Newsletters

Take a look below at the main highlights for the BioMed Alliance and developments at EU level in March 2026. In this edition, you’ll find updates on BioMed’s MDR & IVDR advocacy activities, recommendations on the Digital Omnibus proposal, the European Parliament event on Reducing Bureaucracy in Clinical Trials, the BioMed statement on the Critical Medicines Act, an update on the new EU Gender Equality Strategy (2026-2030), the EU call for evidence on the Global Health Resilience Initiative, the More-EUROPA survey on patient registries in EU medicines decision-making, a consultation on the Cybersecurity Package, as well as members’ news and information about other upcoming events.

Take a look below at the main highlights for the BioMed Alliance and developments at EU level in February 2026. In this edition, you will find an update on medical education activities, details about our breakout session at the European Commission’s High-Level Conference on Medical Devices and IVDs, information on the FAST-EU pilot project, an update on ongoing discussions on the European Competitiveness Fund (ECF) in the European Parliament, updates on the 2026 Horizon Europe health calls for proposals, an announcement of the BioMed Spring Meeting 2026, members’ news, and information on other upcoming events.

Take a look below at the main highlights for the BioMed Alliance and developments at EU level in January 2026. In this first edition of the year, you will find updates on BioMed MDR & IVDR advocacy activities, recommendations from the Bureaucracy in Clinical Trials Coalition, the European Commission implementing act designating new reference laboratories for high-risk IVDs, the political agreement on the reform of EU pharmaceutical legislation, and the Commission’s Safe Hearts Plan. You will also find information on the open consultation for the Action Plan for Women in Research, Innovation, and Startups, the IHI call for innovative health projects, and upcoming events.

Read highlights from the BioMed Alliance and EU developments in October 2025. This edition features updates on our upcoming General Assembly programme, the new AI Task Force, and recommendations to streamline digital health regulations. It also covers ongoing MDR/IVDR advocacy, including input to the Commission’s targeted revision and a visit to UZ Leuven. Other topics include new proposals to reduce clinical trial bureaucracy, the Commission’s latest AI strategies, and open consultations on the ERA Act, BeWell project, and TEHDAS2. The Update concludes with members’ news and upcoming events.

Following the summer break, September brought a series of key developments in biomedical and health policy. In this edition, you will find updates on the Alliance’s response to the European Commission’s call for evidence on the upcoming European Research Area (ERA) Act, a joint open letter on the EU Medical Devices Regulation (MDR), and new CORE-MD recommendations on clinical evidence for high-risk medical devices. We also highlight the 2025 State of the Union Address, the European Research and Innovation (R&I) Days, and upcoming events.

Take a look at the main highlights for BioMed Alliance and at EU level in August 2025. As summer draws to a close, key developments continue both within the BioMed Alliance and in European health policy. This edition includes updates on our upcoming General Assembly, our Statement on the Pharmaceutical Legislation Reform, the newly established expert panel on paediatrics and rare diseases, the public consultation on the ERA Act, a consultation related to the EU4Health programme, as well as information on upcoming events.